{"id":875176,"date":"2025-08-13T09:18:54","date_gmt":"2025-08-13T13:18:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/"},"modified":"2025-08-13T09:18:54","modified_gmt":"2025-08-13T13:18:54","slug":"maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/","title":{"rendered":"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>CHICAGO , Aug.  13, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled \u201cMercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,\u201d was invented by MAIA\u2019s Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD.<\/p>\n<p align=\"justify\">\u201cMercaptopurine nucleoside analogues are cancer-fighting immunosuppressive agents that disrupt the structure and function of telomeres and reduce immune system activity, interfering with the growth of cancer cells and causing programmed cancer cell death. As an important extension of MAIA\u2019s innovative cancer treatment platform, these new compounds are key next-generation telomere-targeting agents with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity,\u201d said Dr. Gryaznov.<\/p>\n<p align=\"justify\">\u201cThe new IP is expected to further secure and expand the value of our first-in-class telomere-targeting compounds across the European scientific community,\u201d added MAIA Chairman and CEO Vlad Vitoc, M.D.<\/p>\n<p align=\"justify\">MAIA\u2019s global patent and patent-pending estate covers several areas including telomerase mediated telomere altering compounds and treatment of therapy-resistant cancers. Further, ateganosine\u2019s immunogenic treatment strategy, which focuses on sequential combination with checkpoint inhibitors, has been filed worldwide. MAIA\u2019s IP portfolio for ateganosine currently comprises 10\u00a0issued patents worldwide including Europe (validated in 19 countries) along with 24\u00a0pending patent applications.<\/p>\n<p>\n        <strong>About Ateganosine<\/strong>\n      <\/p>\n<p align=\"justify\">Ateganosine (THIO, 6-thio-dG or 6-thio-2\u2019-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2\u2019-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS\/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type\u2013specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.<\/p>\n<p>\n        <strong>About MAIA Biotechnology, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0onX07HbwydOERdSalsuZ4baZdf3vTMbi4AdTTvH6MPhRFUE7CFJaSBInhB0MqUbELji_fiFDYcXtSMn7V7Ow7n4IQSm24RZs7pPO9c4iF8=\" rel=\"nofollow\" target=\"_blank\">www.maiabiotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, \u201cMAIA,\u201d \u201cCompany,\u201d \u201cwe,\u201d \u201cour,\u201d and \u201cus\u201d refers to MAIA Biotechnology, Inc. and its subsidiaries.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>+1 (872) 270-3518<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_h3Yjp645RrY5zI8QY2SZz0I2DG-c3uyll_qUp_1CWoGcg5JRWLHZNZQ1Yz-_0zVQkAo0uuC00PFgGwePxPCyg==\" rel=\"nofollow\" target=\"_blank\">ir@maiabiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzZiYzY4YzItMTgyNS00ZWM1LTk4NjItMGIzYjc5ZThkOTk2LTUwMDEyMjI1Ny0yMDI1LTA4LTEzLWVu\/tiny\/MAIA-Biotechnology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells\u00a0 CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled \u201cMercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,\u201d was invented by MAIA\u2019s Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD. \u201cMercaptopurine nucleoside analogues are cancer-fighting immunosuppressive agents that disrupt the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-875176","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells\u00a0 CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled \u201cMercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,\u201d was invented by MAIA\u2019s Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD. \u201cMercaptopurine nucleoside analogues are cancer-fighting immunosuppressive agents that disrupt the &hellip; Continue reading &quot;MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-13T13:18:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy\",\"datePublished\":\"2025-08-13T13:18:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/\"},\"wordCount\":892,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/\",\"name\":\"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==\",\"datePublished\":\"2025-08-13T13:18:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/","og_locale":"en_US","og_type":"article","og_title":"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - Market Newsdesk","og_description":"Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells\u00a0 CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) &#8212; MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled \u201cMercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,\u201d was invented by MAIA\u2019s Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD. \u201cMercaptopurine nucleoside analogues are cancer-fighting immunosuppressive agents that disrupt the &hellip; Continue reading \"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-13T13:18:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy","datePublished":"2025-08-13T13:18:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/"},"wordCount":892,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/","name":"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==","datePublished":"2025-08-13T13:18:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMTU2NCM3MDk3MDM3IzUwMDEyMjI1Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-granted-european-patent-for-next-generation-telomere-targeting-agents-for-cancer-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/875176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=875176"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/875176\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=875176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=875176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=875176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}